Developer docs
API playgroundTry for free, no card

Search company profiles

Broken String Biosciences

Full company profile

uuid0000q6n

Namestring
Broken String Biosciences
Legal namestring
Broken String Biosciences Limited
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Broken String Biosciences is a privately-held biotechnology company headquartered in Cambridge (Hinxton), United Kingdom, founded in 2017 around research spun out of Cardiff University with AstraZeneca as an industrial sponsor. The company develops INDUCE-seq, a PCR-free, in cellulo platform that directly labels and captures DNA double-strand breaks genome-wide, enabling unbiased on- and off-target analysis for gene editing programs. Its commercial offering centers on the BreakMap kitted workflow, the INDUCE-seq Analysis cloud-based bioinformatics platform, and a suite of services spanning discovery screening, base editing support, and IND-enabling studies, with the Catalyst Early Access Program enabling customers to run the platform in-house. The company is also developing SafeGuide, an AI gRNA selection tool in partnership with BioLizard.

Short descriptiontext

Broken String Biosciences is a UK-based biotechnology company that sells the INDUCE-seq platform and BreakMap kits for genome-wide, cell-based detection of DNA breaks, serving cell and gene therapy developers working on CRISPR, base editing, and prime editing programs from discovery through IND-enabling studies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLittle Chesterford, United Kingdom
HQ citystring
Little Chesterford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genome-wide DNA break detection, gene editing safety analysis, off-target characterization, next-generation sequencing assays, cell and gene therapy tools
Industry3 codes
PRIMARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Genomic Safety Analysis Tools
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1INDUCE-seq platform services
TypeProfessional Services
Description

Broken String offers its INDUCE-seq platform as a lab-based service through its own facilities, enabling gene editing therapy developers to detect on- and off-target edits at high resolution. The company also offers the Catalyst Early Access Program for developers to use the platform in their own labs.

brokenstringbio.com
2BreakMap kits
TypeOne Time License
Description

BreakMap is an end-to-end kitted workflow (24 samples per kit configuration) that includes molecular biology reagents, buffers, DNA purification beads for NGS library preparation, and access to the BreakMap cloud-based analysis platform. Kits are sold with associated support services including comprehensive onboarding, user guides, videos, and in-person training.

brokenstringbio.com
3Cloud-based bioinformatics access
TypeSubscription Recurring
Description

Access to the BreakMap cloud-based analysis platform is included with kit purchases, enabling secure bioinformatics that translates raw sequencing data into ranked, actionable insights.

brokenstringbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Quote-based pricing for BSB Kits and Services
ModelOtherBilling cadencePay-as-you-go
Notes

Prices are set out in the Purchase Order or applicable Quotation. BSB may issue invoices for relevant products and services. Customer pays within 30 days after invoice date. All amounts shown exclusive of VAT and applicable taxes.

brokenstringbio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1INDUCE-seq®
Description

Core platform technology for genome-wide detection and quantification of DNA breaks in gene editing applications, enabling on- and off-target analysis

brokenstringbio.com
+3 more records
Core offering1 text field

Broken String Biosciences develops and commercializes the INDUCE-seq® platform, a PCR-free, in cellulo technology that directly labels and quantifies DNA double-strand breaks across the genome. The platform is sold as the BreakMap™ kitted workflow (reagents, library prep consumables, and cloud-based bioinformatics) and supported by lab-based services spanning discovery screening, base editing assessment, and IND-enabling off-target characterization for cell and gene therapy developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results delivered in days compared to months with traditional approaches
+2 more records
Product overview1 text field

Broken String Biosciences offers a unified portfolio centered on the INDUCE-seq® platform, a PCR-free, cell-based technology for genome-wide DNA break detection and quantification. The commercial product is delivered as the BreakMap™ kit, which packages INDUCE-seq reagents with integrated cloud-based bioinformatics analysis and comprehensive onboarding. Supporting services span discovery screening, base editing applications, and IND-enabling studies with FDA Master File reference documentation. The company is developing SafeGuide, an AI-powered gRNA selection tool in partnership with BioLizard, to complement the platform with predictive analytics capabilities.

Product and service8 records
1INDUCE-seq® Platform
CategoryCore technology platform
Description

Scalable, cell-based, PCR-free platform for genome-wide detection and quantification of DNA double-strand breaks. Directly labels and captures DNA breaks within fixed and permeabilised cells, enabling unbiased on- and off-target editing analysis. Compatible with any cell type and any nuclease-based editor, supporting CRISPR, base editing, and prime editing programs.

2BreakMap™ Kit
CategoryReagent kit product
Description

End-to-end kitted workflow (24 samples per kit configuration) for in-house genome-wide on- and off-target analysis. Includes molecular biology reagents and buffers, DNA purification beads for NGS library preparation, and access to the cloud-based analysis platform. Sold with onboarding, user guides, videos, and in-person training.

3INDUCE-seq® Analysis (Cloud Bioinformatics Platform)
CategoryBioinformatics software platform
Description

Purpose-built, cloud-based bioinformatics platform that converts INDUCE-seq sequencing data into ranked, decision-ready outputs including nominated putative off-target break sites, annotated tables, and visualizations. Features precise break localization, normalized treated:control analysis, break site annotation with biological context, and probabilistic nomination of high-confidence candidate sites; typical analysis time under 2 hours.

4IND-Enabling Studies Service
CategoryApplication service
5IND-Enabling Studies Service
CategoryApplication service
Description

Regulatory-focused off-target characterization service supporting IND submissions. Provides genome-wide, cell-based datasets aligned with FDA expectations, identification of treatment-induced off-target sites for confirmation strategies, and access to FDA Master File reference documentation.

6Base Editing Support Service
CategoryApplication service
Description

Genome-wide, cell-based assessment solutions for adenine base editing (ABE) and cytosine base editing (CBE) programs. Enables simultaneous evaluation of editing-associated signals and unexpected off-target DNA break events within the same cellular context, with dedicated workflows for early access partners.

7Discovery Screening Service
CategoryApplication service
Description

Early-stage gene editing screening service enabling confident assessment of on- and off-target editing outcomes. Designed to scale alongside modern screening approaches and to support higher-throughput automated laboratory environments without compromising data quality.

8Catalyst Early Access Program
CategoryService program
Description

Early access program that allows selected gene editing therapy developers to use the INDUCE-seq® platform in their own laboratories. Cell- and nuclease-agnostic, enabling direct measurement in clinically relevant samples and supporting rapid iteration on guide RNA optimization and off-target characterization.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Distributor appointed across Southeast Asia (Singapore, Malaysia, Indonesia, Vietnam, Thailand) to bring INDUCE-seq directly to regional life science and pharmaceutical sectors to accelerate clinical impact.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-05
Description

Broken String is a member of the NIST Genome Editing Consortium, playing a key role in developing gold-standard safety testing for gene-editing therapies. The company partners with other leaders in the field to publish findings and engage with regulators to promote adoption of its technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-10
Description

Partnership to develop SafeGuide, an AI tool for selecting safer, better guide RNAs. The project benefits from a $935,000 grant through the Eurostars-3 program. Broken String contributes data and expertise from its INDUCE-seq platform while BioLizard develops predictive algorithms that integrate genomic break data with sequence and structural features to recommend gRNAs with high on-target efficacy and low off-target risk.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Cross-sector committee where 30 partner companies including major biopharma partners are helping advance breakthrough technologies that improve human health in the cell and gene therapy space.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-07
Description

Research collaboration to apply INDUCE-seq technology to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS). Partnership combines Prof Simon Boulton's DNA double-strand break research with Prof Rickie Patani's ALS disease mechanism research. Secured via the Crick's Business Engagement Fund supported by MRC-UKRI.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provides CRISPR gene editing tools, engineered cells, and bioinformatics services supporting therapeutic developers. Directly comparable to Broken String as a tools/services provider serving the same gene editing customer base with overlapping off-target analysis and gRNA design offerings.

TypeDirect peer
Description

Offers gene editing and cell line engineering services, including off-target characterisation and cell-based assay support for therapeutic developers. Closely comparable to Broken String's IND-enabling and discovery screening services, and notably the alma mater of Broken String's CEO.

TypeBroad incumbent
Description

Manufactures plasmids, mRNA, and proteins used in cell and gene therapy development, with services supporting safety and analytical testing. Overlaps with Broken String as a partner/supplier to gene therapy developers, though broader in scope.

TypeBroad incumbent
Description

Single-cell and spatial genomics platform used across gene editing and cell therapy programmes. Compares to Broken String as a genomics tools vendor to the same customer base; Broken String's ex-board member Brad Crutchfield was previously CCO of 10x Genomics.

TypeBroad incumbent
Description

Dominant NGS platform provider underpinning most sequencing-based off-target assays including INDUCE-seq. Illumina Ventures is also a Broken String investor, highlighting the strategic adjacency; comparable as a broader genomics tools incumbent whose sequencing infrastructure underpins the gene editing safety workflow.

TypeBroad incumbent
Description

Large CRO with significant gene therapy and cell therapy safety/biologics testing services. Comparable to Broken String's IND-enabling services business as a broader incumbent CRO serving the same therapeutic developers with safety and analytical services.

TypeBroad incumbent
Description

Cell and gene therapy CDMO with development, manufacturing, and analytical services for advanced therapies. Compares to Broken String as a service provider supporting gene therapy programmes through IND-enabling stages, with broader CDMO scale.

TypeEmerging player
Description

DNA synthesis platform with growing footprint in synthetic biology and gene editing tools, including gRNA libraries and target enrichment products. Adjacent to Broken String's customer base of gene editing developers, with overlapping commercial channels.

TypeBroad incumbent
Description

Major supplier of oligonucleotides, gRNAs, and CRISPR reagents used in gene editing workflows. Comparable as a tools vendor serving the same gene editing developers; supplies adjacent parts of the editing workflow that Broken String's off-target platform characterises.

TypeEmerging player
Description

Develops CRISPR-based genome editing technologies with both therapeutic and tools businesses. Comparable as a gene editing specialist with internal platform technology targeting therapeutic developers, though Caribou's tools offering is more nascent than Broken String's commercial platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Broken String Biosciences

Genomic Safety Analysis Toolsbrokenstringbio.com

Broken String Biosciences is a UK-based biotechnology company that sells the INDUCE-seq platform and BreakMap kits for genome-wide, cell-based detection of DNA breaks, serving cell and gene therapy developers working on CRISPR, base editing, and prime editing programs from discovery through IND-enabling studies.

What Broken String Biosciences does

Broken String Biosciences is a privately-held biotechnology company headquartered in Cambridge (Hinxton), United Kingdom, founded in 2017 around research spun out of Cardiff University with AstraZeneca as an industrial sponsor. The company develops INDUCE-seq, a PCR-free, in cellulo platform that directly labels and captures DNA double-strand breaks genome-wide, enabling unbiased on- and off-target analysis for gene editing programs. Its commercial offering centers on the BreakMap kitted workflow, the INDUCE-seq Analysis cloud-based bioinformatics platform, and a suite of services spanning discovery screening, base editing support, and IND-enabling studies, with the Catalyst Early Access Program enabling customers to run the platform in-house. The company is also developing SafeGuide, an AI gRNA selection tool in partnership with BioLizard.

Broken String Biosciences firmographics

Firmographics
Name
Broken String Biosciences
Legal name
Broken String Biosciences Limited
Website
https://brokenstringbio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Broken String Biosciences is a UK-based biotechnology company that sells the INDUCE-seq platform and BreakMap kits for genome-wide, cell-based detection of DNA breaks, serving cell and gene therapy developers working on CRISPR, base editing, and prime editing programs from discovery through IND-enabling studies.
Ownership category
akta.pro rank

Broken String Biosciences industry classification

Industry
Product category
Genomic Safety Analysis Tools
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAK
Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Genome-wide DNA break detection
  • Gene editing safety analysis
  • Off-target characterization
  • Next-generation sequencing assays
  • Cell and gene therapy tools

Where Broken String Biosciences is headquartered

Location

Headquarters

HQ city
Little Chesterford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Broken String Biosciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. INDUCE-seq platform services: Broken String offers its INDUCE-seq platform as a lab-based service through its own facilities, enabling gene editing therapy developers to detect on- and off-target edits at high resolution. The company also offers the Catalyst Early Access Program for developers to use the platform in their own labs.
  2. BreakMap kits: BreakMap is an end-to-end kitted workflow (24 samples per kit configuration) that includes molecular biology reagents, buffers, DNA purification beads for NGS library preparation, and access to the BreakMap cloud-based analysis platform. Kits are sold with associated support services including comprehensive onboarding, user guides, videos, and in-person training.
  3. Cloud-based bioinformatics access: Access to the BreakMap cloud-based analysis platform is included with kit purchases, enabling secure bioinformatics that translates raw sequencing data into ranked, actionable insights.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for BSB Kits and Services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Broken String Biosciences product offering

Product offering

Core offering

Broken String Biosciences develops and commercializes the INDUCE-seq® platform, a PCR-free, in cellulo technology that directly labels and quantifies DNA double-strand breaks across the genome. The platform is sold as the BreakMap™ kitted workflow (reagents, library prep consumables, and cloud-based bioinformatics) and supported by lab-based services spanning discovery screening, base editing assessment, and IND-enabling off-target characterization for cell and gene therapy developers.

Product overview

Broken String Biosciences offers a unified portfolio centered on the INDUCE-seq® platform, a PCR-free, cell-based technology for genome-wide DNA break detection and quantification. The commercial product is delivered as the BreakMap™ kit, which packages INDUCE-seq reagents with integrated cloud-based bioinformatics analysis and comprehensive onboarding. Supporting services span discovery screening, base editing applications, and IND-enabling studies with FDA Master File reference documentation. The company is developing SafeGuide, an AI-powered gRNA selection tool in partnership with BioLizard, to complement the platform with predictive analytics capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • INDUCE-seq®: Core platform technology for genome-wide detection and quantification of DNA breaks in gene editing applications, enabling on- and off-target analysis
  • BreakMap™
  • SafeGuide
  • Catalyst Program

Products and services

  • INDUCE-seq® Platform Scalable, cell-based, PCR-free platform for genome-wide detection and quantification of DNA double-strand breaks. Directly labels and captures DNA breaks within fixed and permeabilised cells, enabling unbiased on- and off-target editing analysis. Compatible with any cell type and any nuclease-based editor, supporting CRISPR, base editing, and prime editing programs.
  • BreakMap™ Kit End-to-end kitted workflow (24 samples per kit configuration) for in-house genome-wide on- and off-target analysis. Includes molecular biology reagents and buffers, DNA purification beads for NGS library preparation, and access to the cloud-based analysis platform. Sold with onboarding, user guides, videos, and in-person training.
  • INDUCE-seq® Analysis (Cloud Bioinformatics Platform) Purpose-built, cloud-based bioinformatics platform that converts INDUCE-seq sequencing data into ranked, decision-ready outputs including nominated putative off-target break sites, annotated tables, and visualizations. Features precise break localization, normalized treated:control analysis, break site annotation with biological context, and probabilistic nomination of high-confidence candidate sites; typical analysis time under 2 hours.
  • IND-Enabling Studies Service
  • IND-Enabling Studies Service Regulatory-focused off-target characterization service supporting IND submissions. Provides genome-wide, cell-based datasets aligned with FDA expectations, identification of treatment-induced off-target sites for confirmation strategies, and access to FDA Master File reference documentation.
  • Base Editing Support Service Genome-wide, cell-based assessment solutions for adenine base editing (ABE) and cytosine base editing (CBE) programs. Enables simultaneous evaluation of editing-associated signals and unexpected off-target DNA break events within the same cellular context, with dedicated workflows for early access partners.
  • Discovery Screening Service Early-stage gene editing screening service enabling confident assessment of on- and off-target editing outcomes. Designed to scale alongside modern screening approaches and to support higher-throughput automated laboratory environments without compromising data quality.
  • Catalyst Early Access Program Early access program that allows selected gene editing therapy developers to use the INDUCE-seq® platform in their own laboratories. Cell- and nuclease-agnostic, enabling direct measurement in clinically relevant samples and supporting rapid iteration on guide RNA optimization and off-target characterization.

Quantifiable outcome

  • Results delivered in days compared to months with traditional approaches
  • +2 more outcomes

Companies that use Broken String Biosciences

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Broken String Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Broken String Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered regional and core.

  • Sciencewerke Pte LtdregionalChannel Partner/ Reseller/ Distributor · 1 January 2026Distributor appointed across Southeast Asia (Singapore, Malaysia, Indonesia, Vietnam, Thailand) to bring INDUCE-seq directly to regional life science and pharmaceutical sectors to accelerate clinical impact.
  • National Institute of Standards and Technology (NIST) Genome Editing ConsortiumcoreStrategic or Co-development Partner · 5 August 2025Broken String is a member of the NIST Genome Editing Consortium, playing a key role in developing gold-standard safety testing for gene-editing therapies. The company partners with other leaders in the field to publish findings and engage with regulators to promote adoption of its technology.
  • BioLizardcoreStrategic or Co-development Partner · 10 July 2025Partnership to develop SafeGuide, an AI tool for selecting safer, better guide RNAs. The project benefits from a $935,000 grant through the Eurostars-3 program. Broken String contributes data and expertise from its INDUCE-seq platform while BioLizard develops predictive algorithms that integrate genomic break data with sequence and structural features to recommend gRNAs with high on-target efficacy and low off-target risk.
  • Health and Environmental Sciences Institute (HESI) CT-TRACS CommitteecoreStrategic or Co-development Partner · 1 January 2025Cross-sector committee where 30 partner companies including major biopharma partners are helping advance breakthrough technologies that improve human health in the cell and gene therapy space.
  • Francis Crick InstitutecoreStrategic or Co-development Partner · 7 May 2024Research collaboration to apply INDUCE-seq technology to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS). Partnership combines Prof Simon Boulton's DNA double-strand break research with Prof Rickie Patani's ALS disease mechanism research. Secured via the Crick's Business Engagement Fund supported by MRC-UKRI.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Broken String Biosciences competitors and assessment

Company assessment

Direct peers

  • Synthego: Provides CRISPR gene editing tools, engineered cells, and bioinformatics services supporting therapeutic developers. Directly comparable to Broken String as a tools/services provider serving the same gene editing customer base with overlapping off-target analysis and gRNA design offerings.
  • Revvity (formerly Horizon Discovery): Offers gene editing and cell line engineering services, including off-target characterisation and cell-based assay support for therapeutic developers. Closely comparable to Broken String's IND-enabling and discovery screening services, and notably the alma mater of Broken String's CEO.

Broad incumbents

  • Aldevron (Danaher): Manufactures plasmids, mRNA, and proteins used in cell and gene therapy development, with services supporting safety and analytical testing. Overlaps with Broken String as a partner/supplier to gene therapy developers, though broader in scope.
  • 10x Genomics: Single-cell and spatial genomics platform used across gene editing and cell therapy programmes. Compares to Broken String as a genomics tools vendor to the same customer base; Broken String's ex-board member Brad Crutchfield was previously CCO of 10x Genomics.
  • Illumina: Dominant NGS platform provider underpinning most sequencing-based off-target assays including INDUCE-seq. Illumina Ventures is also a Broken String investor, highlighting the strategic adjacency; comparable as a broader genomics tools incumbent whose sequencing infrastructure underpins the gene editing safety workflow.
  • Charles River Laboratories: Large CRO with significant gene therapy and cell therapy safety/biologics testing services. Comparable to Broken String's IND-enabling services business as a broader incumbent CRO serving the same therapeutic developers with safety and analytical services.
  • Catalent (Novo Holdings): Cell and gene therapy CDMO with development, manufacturing, and analytical services for advanced therapies. Compares to Broken String as a service provider supporting gene therapy programmes through IND-enabling stages, with broader CDMO scale.
  • Integrated DNA Technologies (IDT, Danaher): Major supplier of oligonucleotides, gRNAs, and CRISPR reagents used in gene editing workflows. Comparable as a tools vendor serving the same gene editing developers; supplies adjacent parts of the editing workflow that Broken String's off-target platform characterises.

Emerging players

  • Twist Bioscience: DNA synthesis platform with growing footprint in synthetic biology and gene editing tools, including gRNA libraries and target enrichment products. Adjacent to Broken String's customer base of gene editing developers, with overlapping commercial channels.
  • Caribou Biosciences: Develops CRISPR-based genome editing technologies with both therapeutic and tools businesses. Comparable as a gene editing specialist with internal platform technology targeting therapeutic developers, though Caribou's tools offering is more nascent than Broken String's commercial platform.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Broken String Biosciences social profiles

Digital presence

Broken String Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Broken String Biosciences leadership team

Management profile

Number of profiles

Profiles14 records

Broken String Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Broken String Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Broken String Biosciences

What does Broken String Biosciences do?

Broken String Biosciences develops and commercializes the INDUCE-seq® platform, a PCR-free, in cellulo technology that directly labels and quantifies DNA double-strand breaks across the genome. The platform is sold as the BreakMap™ kitted workflow (reagents, library prep consumables, and cloud-based bioinformatics) and supported by lab-based services spanning discovery screening, base editing assessment, and IND-enabling off-target characterization for cell and gene therapy developers.

Is Broken String Biosciences a public or private company?

Broken String Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Broken String Biosciences founded?

Broken String Biosciences was founded in 2017. It employs 11 to 50 people.

Where is Broken String Biosciences based?

Broken String Biosciences is headquartered in Little Chesterford, United Kingdom, in the Europe region.

How does Broken String Biosciences make money?

Three revenue lines are on record. INDUCE-seq platform services are the primary driver. The others are breakMap kits and cloud-based bioinformatics access.

Who are Broken String Biosciences's main competitors?

Direct peers on record are Synthego and Revvity (formerly Horizon Discovery). Broad incumbents are Aldevron (Danaher), 10x Genomics, Illumina, Charles River Laboratories, Catalent (Novo Holdings) and Integrated DNA Technologies (IDT, Danaher). Emerging players are Twist Bioscience and Caribou Biosciences.

Does Broken String Biosciences have an API?

No public API is recorded for Broken String Biosciences.

What industry is Broken String Biosciences in?

Broken String Biosciences's product category is Genomic Safety Analysis Tools. Its primary akta.pro industry code is HLAAACAK, Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 541714 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsBaseMap ABE Launched for Off-Target Characterization in Base Editing Therapeutic DevelopmentBroken String Biosciences launched BaseMap™ ABE, a platform based on its INDUCE-seq® technology designed to characterize off-target effects in adenine base editing therapeutic development. The tool provides genome-wide data from biologically relevant cells to help researchers identify unintended editing events and optimize guide selection. This launch marks the first phase of the company's expansion into base editing applications via an Early Access Program.PMLiVEBroken String Biosciences appoints Bruce Eaton as Chairman of the BoardBroken String Biosciences has appointed Bruce Eaton as Chairman of the Board to drive the global commercialisation of its INDUCE-seq platform. This strategic move follows the company's recent submission of an FDA Master File for the technology, which aims to streamline regulatory pathways for gene editing therapeutics.BioSpaceBroken String Biosciences Rebrands to Reflect Strategic Evolution as Demand Grows for Unbiased Genome-wide Off-target AnalysisBroken String Biosciences, a Cambridge-based biotechnology company, has announced a strategic rebrand and comprehensive website redesign to reflect its transition from a specialist technology provider to a commercially focused partner supporting gene editing programs from discovery through IND-enabling studies. The rebrand follows the November 2025 appointment of Terry Pizzie as CEO and aligns the company's identity with its INDUCE-seq platform, which provides genome-wide detection and quantification of DNA breaks for therapeutic developers facing increasing regulatory demands for off-target safety data. The company says its technology enables researchers to generate high-quality, genome-wide safety data in their own labs, supporting earlier and more confident decision-making in therapeutic development.MorningstarBroken String Biosciences Rebrands to Reflect Strategic Evolution as Demand Grows for Unbiased Genome-wide Off-target AnalysisBroken String Biosciences, a UK-based biotechnology company, announced a rebrand and comprehensive website launch as part of its strategic repositioning from a specialist technology provider to a commercially focused partner supporting gene editing programs. The rebrand follows the November 2025 appointment of Terry Pizzie as CEO and aligns the company's brand identity with its INDUCE-seq platform capabilities for genome-wide detection and quantification of DNA breaks. The company is positioning itself to address increasing regulatory demands for cell-based off-target assessment in investigational new drug submissions.Business WeeklyPizzie named CEO as Broken String guns for gene editing gloryBroken String has appointed Terry Pizzie as CEO as part of a management restructure to drive commercialization of its INDUCE-seq® platform for gene editing therapeutic developers worldwide. Pizzie previously guided Horizon Discovery through its $383 million acquisition by PerkinElmer in 2020. The platform cuts candidate screening timelines from months to days by enabling faster, more reliable quantification of on- and off-target gene editing events.Business Wire BlogBroken String Biosciences Announces New Leadership to Drive Commercialization of INDUCE-seq® Platform for Gene Editing On- and Off-target CharacterizationBroken String Biosciences announced the appointment of Terry Pizzie as CEO to drive the commercialization of its INDUCE-seq® platform, which maps DNA double-strand breaks to measure on- and off-target gene editing events for cell and gene therapy developers worldwide. The company is transitioning from a pioneering technology developer to a fully commercial organization, with co-founder Felix Dobbs shifting to COO and Professor Simon Reed continuing as CSO. Recent data presented at the Cell & Gene Meeting on the Mesa 2025 demonstrated that INDUCE-seq® can reduce candidate screening timelines from months to days, and the company has partnered with BioLizard to develop an AI tool called SafeGuide for selecting safer guide RNAs.RegmednetCell therapy weekly: breakthrough in bioprinted adrenal tissuesPreclinical data presented by Aspect Biosystems demonstrated that their bioprinted tissue therapeutics can restore adrenal function in animal models of primary adrenal insufficiency. Additionally, Broken String Biosciences and BioLizard announced a partnership to develop an AI tool to enhance gene editing, while Genascence Corporation received Regenerative Medicine Advanced Therapy designation from the FDA for its gene therapy for knee osteoarthritis. These advancements indicate significant progress in regenerative medicine and gene therapy.Business Wire BlogBroken String Biosciences and BioLizard to Develop AI for Faster, Safer Gene EditingBroken String Biosciences and BioLizard announced SafeGuide, an AI tool for selecting safer guide RNAs for gene editing, backed by a $935,000 Eurostars grant. The tool uses Broken String's INDUCE-seq platform data to predict on-target efficacy and off-target risk, aiming to reduce trial-and-error testing and R&D costs.